PROPRIETARY BENEFITS

  • De-risked due to approved API and proven delivery system
  • Patent reinforcing to further protect technology
  • Additional significant revenue from exclusive manufacturing contracts

Interested parties may contact:

Mark Udell, Chief Financial Officer at

Mudell@curepharma.com